The Renin-Angiotensin-Aldosterone System: Approaches to Guide Angiotensin-Converting Enzyme Inhibition in Patients with Coronary Artery Disease

被引：25

作者：

Brugts, J. J. ^{[1
]}

den Uil, C. A. ^{[1
]}

Danser, A. H. J. ^{[2
]}

Boersma, E. ^{[1
]}

机构：

[1] Erasmus MC, Dept Cardiol, Thoraxctr, NL-3015 CE Rotterdam, Netherlands

[2] Erasmus MC, Dept Pharmacol, NL-3015 CE Rotterdam, Netherlands

来源：

CARDIOLOGY | 2009年 / 112卷 / 04期

关键词：

Angiotensin-converting enzyme inhibitors; Angiotensin; Coronary artery disease; Pharmacogenetics; Prevention; RECEPTOR GENE POLYMORPHISMS; ISCHEMIC-HEART-DISEASE; MAJOR RISK-FACTOR; MYOCARDIAL-INFARCTION; INSERTION/DELETION POLYMORPHISM; CARDIOVASCULAR-DISEASE; DELETION POLYMORPHISM; ACE-INHIBITORS; BLOOD-PRESSURE; PLASMA ANGIOTENSINOGEN;

D O I：

10.1159/000159124

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Drugs that modulate the renin-angiotensin-aldosterone system (RAAS) play an important role in modern cardiovascular prevention strategies. Inhibitors of the RAAS, in particular angiotensin-converting enzyme (ACE) inhibitors, have been proven to be beneficial in specific patient groups, including patients with hypertension, heart failure, diabetes mellitus and stable coronary artery disease. Although clinical trials demonstrated a rather consistent beneficial effect of ACE inhibitors across groups of patients based on clinical characteristics, the variability in treatment response on the individual patient level is extensive. Recent publications suggest that genetic polymorphisms in the RAAS are related to cardiovascular risk. Genetic variability also seems associated with the response to ACE inhibitor therapy, and can probably be used to tailor treatment. This review discusses several approaches to guide ACE inhibitor therapy in patients with coronary artery disease. In addition, the potential impact of pharmacogenetics regarding this particular topic is highlighted. Copyright (C) 2008 S. Karger AG, Basel

引用

页码：303 / 312

页数：10

共 63 条

[1] ACE gene polymorphism in cardiovascular disease -: Meta-analyses of small and large studies in whites [J].

Agerholm-Larsen, B ;

Nordestgaard, BG ;

Tybjaerg-Hansen, A .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (02) :484-492

[2] ACE gene polymorphism: Ischemic heart disease and longevity in 10150 individuals - A case-referent and retrospective cohort study based on the Copenhagen City Heart Study [J].

AgerholmLarsen, B ;

Nordestgaard, BG ;

Steffensen, R ;

Sorensen, TIA ;

Jensen, G ;

TybjaergHansen, A .

CIRCULATION, 1997, 95 (10) :2358-2367

[3] Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphisms: association with early coronary disease [J].

Alvarez, R ;

Reguero, JR ;

Batalla, A ;

Iglesias-Cubero, G ;

Cortina, A ;

Alvarez, V ;

Coto, E .

CARDIOVASCULAR RESEARCH, 1998, 40 (02) :375-379

[4]

Amant C, 1997, CIRCULATION, V96, P56

[5] Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment - The genetics of hypertension-associated treatment (GenHAT) study [J].

Arnett, DK ;

Davis, BR ;

Ford, CE ;

Boerwinkle, E ;

Leiendecker-Foster, C ;

Miller, MB ;

Black, H ;

Eckfeldt, JH .

CIRCULATION, 2005, 111 (25) :3374-3383

[6] Angiotensin converting enzyme inhibition in cardiovascular risk populations: a practical approach to identify the patient who will benefit most [J].

Asselbergs, Folkert W. ;

van Gilst, Wiek H. .

CURRENT OPINION IN CARDIOLOGY, 2007, 22 (04) :267-272

[7] Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor [J].

Batenburg, Wendy W. ;

Krop, Manne ;

Garrelds, Ingrid M. ;

de Vries, Rene ;

de Bruin, Rene J. A. ;

Burckle, Celine A. ;

Muller, Dominik N. ;

Bader, Michael ;

Nguyen, Genevieve ;

Danser, A. H. Jan .

JOURNAL OF HYPERTENSION, 2007, 25 (12) :2441-2453

[8] Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients [J].

Bis, JC ;

Smith, NL ;

Psaty, BM ;

Heckbert, SR ;

Edwards, KL ;

Lemaitre, RN ;

Lumley, T ;

Rosendaal, FR .

AMERICAN JOURNAL OF HYPERTENSION, 2003, 16 (12) :1011-1017

[9] Mortality in patients with hypertension on angiotensin-I converting enzyme (ACE)-inhibitor treatment is influenced by the ACE insertion/deletion polymorphism [J].

Bleumink, GS ;

Schut, AFC ;

Sturkenboom, MCJM ;

van Duijn, CM ;

Deckers, JW ;

Hofman, A ;

Kingma, JH ;

Witteman, JCM ;

Stricker, BHC .

PHARMACOGENETICS AND GENOMICS, 2005, 15 (02) :75-81

[10]

Braunwald E, 2004, NEW ENGL J MED, V351, P2058

← 1 2 3 4 5 6 7 →